Truist Financial Corp Lowers Position in Stryker Corporation $SYK

Key Points

• Truist Financial trimmed its stake in Stryker by 4.1%, selling 4,504 shares and holding 104,123 shares worth about $36.6 million after the quarter.
• Stryker missed quarterly expectations (EPS $2.60 vs. $2.98; revenue $6.02B vs. $6.34B) but set FY‑2026 guidance of $14.90–15.10 EPS; analysts maintain a "Moderate Buy" consensus with an average target of $395.48.
• Institutional ownership is high at 77.09%, with mixed activity in the quarter — some managers (e.g., Czech National Bank, Daymark) increased holdings while others initiated new stakes (Terra Alpha, Kepler Cheuvreux).

Truist Financial Corp lessened its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 4.1% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 104,123 shares of the medical technology company's stock after selling 4,504 shares during the period. Truist Financial Corp's holdings in Stryker were worth $36,596,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Czech National Bank raised its position in shares of Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company's stock worth $31,898,000 after buying an additional 3,366 shares in the last quarter. Davis R M Inc. raised its position in shares of Stryker by 1.8% in the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company's stock worth $51,285,000 after buying an additional 2,512 shares in the last quarter. Terra Alpha Investments LLC purchased a new stake in Stryker during the third quarter valued at about $1,216,000. Kepler Cheuvreux Suisse SA purchased a new stake in Stryker during the third quarter valued at about $27,952,000. Finally, Daymark Wealth Partners LLC raised its position in Stryker by 436.0% during the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company's stock valued at $16,119,000 after purchasing an additional 37,307 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Ratings Changes

A number of research firms have weighed in on SYK. BTIG Research lowered their price target on Stryker from $397.00 to $379.00 and set a "buy" rating on the stock in a research report on Friday, May 1st. Truist Financial restated a "hold" rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday. Piper Sandler restated an "overweight" rating on shares of Stryker in a research report on Tuesday, January 27th. Barclays lowered their price target on Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, Weiss Ratings downgraded Stryker from a "hold (c+)" rating to a "hold (c)" rating in a research report on Monday. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $395.48.

Stryker Stock Up 1.5%

Shares of NYSE:SYK opened at $295.39 on Wednesday. The stock's 50-day moving average price is $343.97 and its 200-day moving average price is $356.28. Stryker Corporation has a 12-month low of $290.17 and a 12-month high of $404.87. The stock has a market capitalization of $113.13 billion, a P/E ratio of 34.19, a price-to-earnings-growth ratio of 1.72 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period last year, the business posted $2.84 earnings per share. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.